Medindia

X

New Chairman of the Board for Oncopeptides AB

Monday, April 19, 2010 Press Release J E 4
Advertisement
STOCKHOLM, April 19, 2010 Oncopeptides AB, a KarolinskaDevelopment portfolio company, today announced that Alan Hulme was electedChairman of the Board at the annual general meeting. Mr Hulme has over 30years experience in the life science business and wide experience in manysectors and geographic locations.

"We are fortunate to have Alan as the Chairman of the Board and I lookforward to his contribution to the development of the company" says Dr JackSpira CEO of Oncopeptides AB.

Conny Bogentoft, CEO of Karolinska Development added "Alan's vastexperience in business development will be of great value to the Company asit now enters into later development phases. This will help Oncopeptidesfulfill its goals, which will further strengthen the Karolinska Developmentportfolio."

Alan Hulme has been involved in the development of many businesses withinthe life sciences sector - covering biotechnology, diagnostics and medicaldevices - and, operating from his base in London, has been engaged in a rangeof international corporate development activities with venture backedcompanies in the sector.

About Oncopeptides AB

Oncopeptides is a privately held company developing pharmaceuticals totreat cancer. The Company has proprietary technology based on creatingpro-drugs with increased efficacy of already known compounds. The leadsubstance, called J1, is presently in a phase IIa clinical trial.Oncopeptides is part of the Karolinska Development portfolio.http://www.oncopeptides.se

About Karolinska Development AB

Karolinska Development manages one of the largest portfolios of lifescience companies in Europe. Using a unique, highly cost efficient businessmodel, the management team guides the commercialization of world-class lifescience innovations, helping to shape the next generation pharmaceuticalindustry. Since 2003, Karolinska Development has built a portfolio of some 40companies; among the Company's projects 12 compounds are undergoing clinicaltrials. The portfolio also includes a total of 21 potential first in classproducts. http://www.karolinskadevelopment.comContact: Karen Frost, +46-70-2047003,karen.frost@karolinskadevelopment.com

SOURCE Karolinska Development AB
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alere's David Wolf Presents 'Measuring and Communi...
S
SOKO Fitness Announces Third Quarter Fiscal 2010 F...